Equities research analysts expect that Aduro Biotech, Inc. (NASDAQ:ADRO) will post sales of $4.18 million for the current quarter, Zacks reports. Three analysts have provided estimates for Aduro Biotech’s earnings, with the highest sales estimate coming in at $5.05 million and the lowest estimate coming in at $3.70 million. Aduro Biotech reported sales of $3.79 million during the same quarter last year, which would suggest a positive year over year growth rate of 10.3%. The firm is expected to report its next quarterly earnings report on Wednesday, November 1st.

On average, analysts expect that Aduro Biotech will report full year sales of $4.18 million for the current year, with estimates ranging from $17.09 million to $19.40 million. For the next fiscal year, analysts expect that the company will report sales of $38.28 million per share, with estimates ranging from $15.02 million to $74.82 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Aduro Biotech.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). The firm had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The business’s revenue for the quarter was down 84.9% on a year-over-year basis. During the same period last year, the company earned $0.03 earnings per share.

A number of research firms have weighed in on ADRO. BidaskClub cut shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Cowen and Company began coverage on shares of Aduro Biotech in a research report on Tuesday, July 18th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $19.00.

Aduro Biotech (NASDAQ:ADRO) traded up 0.89% during trading on Friday, reaching $11.30. 269,266 shares of the company traded hands. The company’s market capitalization is $843.12 million. The firm has a 50-day moving average price of $11.67 and a 200-day moving average price of $10.97. Aduro Biotech has a 52 week low of $8.75 and a 52 week high of $15.52.

COPYRIGHT VIOLATION NOTICE: “Analysts Expect Aduro Biotech, Inc. (ADRO) Will Post Quarterly Sales of $4.18 Million” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/15/analysts-expect-aduro-biotech-inc-adro-will-post-quarterly-sales-of-4-18-million.html.

In other news, VP Blaine Templeman sold 3,557 shares of the company’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $10.99, for a total transaction of $39,091.43. Following the completion of the sale, the vice president now owns 65,275 shares of the company’s stock, valued at $717,372.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jennifer Lew sold 12,000 shares of the company’s stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $11.19, for a total transaction of $134,280.00. Following the sale, the insider now directly owns 54,595 shares of the company’s stock, valued at approximately $610,918.05. The disclosure for this sale can be found here. Insiders have sold 467,261 shares of company stock valued at $5,359,431 over the last 90 days. 6.60% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its holdings in shares of Aduro Biotech by 11.2% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in shares of Aduro Biotech by 15.9% during the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after buying an additional 2,119 shares in the last quarter. Tudor Investment Corp ET AL grew its holdings in shares of Aduro Biotech by 34.8% during the first quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock worth $166,000 after buying an additional 3,984 shares in the last quarter. Voya Investment Management LLC grew its holdings in shares of Aduro Biotech by 15.3% during the second quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after buying an additional 2,515 shares in the last quarter. Finally, American International Group Inc. grew its holdings in shares of Aduro Biotech by 7.1% during the first quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after buying an additional 1,447 shares in the last quarter. 35.05% of the stock is owned by institutional investors and hedge funds.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Get a free copy of the Zacks research report on Aduro Biotech (ADRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.